Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.

Clinical pharmacology and therapeutics - 1 Aug 2010

Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen P J, Backman J T

Abstract excerpt

According to available information, montelukast is metabolized by cytochrome P450 (CYP) 3A4 and 2C9. In order to study the significance of CYP2C8 in the pharmacokinetics of montelukast, 10 healthy subjects were administered gemfibrozil 600 mg or placebo twice daily for 3 days, and 10 mg montelukast on day 3, in a randomized, crossover study. Gemfibrozil increased the mean area under the plasma concentration-time...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetates
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2C8

Share to Glucuronides

Share to Hypolipidemic Agents

Share to Microsomes, Liver

Share to Sulfides

Source

Identifiers

PMID: 20592724
DOI: 10.1038/clpt.2010.73

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.PMID 20592724Read ↗

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Semantic proximity Read ↗

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.Semantic proximity Read ↗

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.Semantic proximity Read ↗

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.Semantic proximity Read ↗

Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.Semantic proximity Read ↗

Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.Semantic proximity Read ↗

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.Semantic proximity Read ↗

UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.Semantic proximity Read ↗

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.